BARDA Funding Tracker
Tracker Details Billions in Taxpayer Funds Supporting COVID-19 R&D Efforts
The U.S. government is spending billions of dollars advancing COVID-19 tests, treatments, and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services, is one of the federal entities leading this effort. In the tables below, we describe BARDA funding awards to date. These include awards for research, development, manufacturing, and procurement.
Last updated November 2, 2020
COVID-19 BARDA Funding Summary
| Type of Product | Count | Total Awarded | Average Award | Lowest Award | Highest Award | Proportion of Total Award |
|---|---|---|---|---|---|---|
| Diagnostic | 44 | 157,819,208 | 4,046,646 | 111,090 | 26,120,000 | 1.1% |
| Therapeutic | 10 | 1,806,556,899 | 180,655,690 | 7,200,000 | 617,724,874 | 12.5% |
| Vaccine | 7 | 10,799,025,492 | 1,542,717,927 | 38,033,570 | 2,479,894,979 | 74.5% |
| Vaccine Administration | 9 | 412,453,989 | 51,556,749 | 432,990 | 204,000,000 | 2.8% |
| Vaccine/Therapeutic Manufacturing | 6 | 1,269,622,467 | 211,603,745 | 31,190,000 | 658,250,000 | 8.8% |
| Rapidly Deployable Capabilities | 5 | 8,216,736 | 1,643,347 | 699,583 | 3,833,363 | 0.1% |
| Other | 5 | 37,926,044 | 7,585,209 | 592,791 | 34,893,033 | 0.3% |
| Total | 86 | 14,491,620,835 | 181,145,260 | 111,090 | 2,479,894,979 |
COVID-19 BARDA Funding Database
Methods: We aggregated entries from the BARDA COVID-19 website. Where indicated, we supplemented the database using press releases. If BARDA was listed as a partner, we included the entire funding amount.| Corporation | Product | Description (quoted excerpt from BARDA) | Amount Awarded | Type of Product | Date (Last modified) | Notes |
|---|---|---|---|---|---|---|
| Beckman Coulter | Monocyte Distribution Width (MDW) hematology-based biomarker | Monocyte Distribution Width (MDW) hematology-based biomarker | 694000 | Diagnostic | 9/28/2020 | |
| Cepheid | Xpert Xpress SARS-CoV-2 test | Development of a Xpert Xpress SARS-CoV-2 rapid diagnostic assay | 3700000 | Diagnostic | 2/25/2020 | |
| Cepheid | Xper Xpress SARS-CoV-2/Flu/RSV EUA test | The EUA Cepheid Xpert Xpress SARS-CoV/Flu/RSV test will detect viral nucleic acid and provides one test that detects and differentiates COVID-19 and Flu during the upcoming Flu season. | 1000000 | Diagnostic | 9/23/2020 | |
| Chembio | DPP® COVID-19 Ag System | SARS-CoV-2 point-of-care antigen detection assay, using Chembio’s patented DPP® (lateral flow based) and DPP Micro Reader for diagnosis of COVID-19 from respiratory specimens. | 628071 | Diagnostic | 7/6/2020 | |
| Cue Inc. | Point-of-Care COVID-19 | The Cue Health Monitoring System w/SARS CoV-2 cartridge is a small, portable sample-to-answer system designed for point-of-care and home use. | 13692370 | Diagnostic | 3/21/2020 | |
| DiaSorin Inc. | LIAISON SARS-CoV-2 IgMTest | A serology test to detect IgM antibodies against SARS-CoV-2 in human serum or plasma, using chemiluminescent immunoassay technology on the fully automated LIAISON® XL platform. The development of this test is being funded by a modification to our existing award with DiaSorin Inc. | 111090 | Diagnostic | 8/6/2020 | |
| DiaSorin Inc. | Liaison SARS-CoV-2 S1/S2 IgG | Serology (antibody) test for COVID-19 on the LIAISON XL platform. This new COVID-19 test is a fully automated, chemiluminescent immunoassay for the qualitative detection of IgG class antibodies against the SARS-CoV-2 virus. | 180045 | Diagnostic | 4/10/2020 | |
| DiaSorin Molecular LLC | SimplexaTM COVID-19 Direct Assay | Development of SimplexaTM COVID-19 Direct Assay | 697423 | Diagnostic | 3/11/2020 | |
| Ellume USA LLC | Unspecified | Two unique test cartridges contain a single-use, digital fluorescent immunoassay antigen test that returns accurate results in 15 minutes or less. One cartridge testing nasal swabs can be read out on two platforms by healthcare professionals, at the point of care or in laboratory settings for higher throughput. A second cartridge is being developed for home use with a self-administered nasal swab. | 11980000 | Diagnostic | 9/30/2020 | Link |
| Empatica, Inc. | Aura | Aura is an early warning platform for COVID-19 infection. This diagnostics platform enables continuous and real-time insight into infection likelihood before symptoms present, through the use of a wearable device and an algorithm that can continuously monitor physiological health markers and produce an output. | 717807 | Diagnostic | 6/18/2020 | |
| Flambeau Diagnostics | Unspecified | A lab module that can be deployed in a mobile van to screen asymptomatic individuals to detect SARS-CoV-2 at low viral levels in saliva samples, returning results in as little as one hour. The system can serve employers, schools and underserved populations. It uses new extraction technology to purify and concentrate viral RNA reliably and quickly. | 4800000 | Diagnostic | 9/29/2020 | Link |
| GenMark Diagnostics, Inc. | ePlex Respiratory Pathogen v2 Panel | An expanded version of GenMarks’s FDA cleared ePlex Respiratory Pathogen (RP) Panel to include assays for the simultaneous detection of SARS-CoV-2 and other respiratory pathogens. | 749000 | Diagnostic | 3/20/2020 | |
| Hememics | Rapid SARS-CoV-2 Antibody Test for HemBox™ Biosensor System | HemBox™ is a Bluetooth-connected POC diagnostic device currently in development for 60-second identification of up to 17 pathogens. This test will detect the presence of SARS-CoV-2 antibodies in 1 drop of blood. This is the same award as the Hememics antigen test. A single award of $638,000 is funding development of the antigen and antibody tests. | 638000 | Diagnostic | 4/9/2020 | |
| Hememics | Rapid SARS-CoV-2 Antigen Test for HemBox™ Biosensor System | HemBox™ is a Bluetooth-connected POC diagnostic device currently in development for 60-second identification of up to 17 pathogens. This test will detect the presence of SARS-CoV-2 antigen in nasal swabs. This is the same award as the Hememics antibody test. A single award of $638,000 is funding development of the antigen and antibody tests. | N/A | Diagnostic | 4/9/2020 | |
| Hologic, Inc. | COVID-19 Testing Products | Expanding production of custom sample collection and processing consumables for COVID-19 tests | 7600000 | Diagnostic | 7/26/2020 | Link |
| Hologic, Inc. | Aptima® SARS-CoV-2 assay | The Aptima® SARS-CoV-2 assay is a molecular diagnostic test that detects SARS-CoV-2, the virus that causes COVID-19 disease, in respiratory specimens. This assay is being developed for use on the Hologic Panther System which is a fully automated, high-throughput molecular diagnostic platform with over 1,000 instruments installed in the U.S. | 13000000 | Diagnostic | 4/29/2020 | |
| Hologic, Inc. | Panther Fusion SARS-CoV-2 Assay | A SARS-CoV-2 Diagnostic Assay based on the widely-used Panther Fusion platform | 699000 | Diagnostic | 3/6/2020 | |
| Immunexpress Inc. | SeptiCyte RAPID Host-Based Sepsis In Vitro Diagnostic | SeptiCyte® RAPID is a host response gene expression, blood-based diagnostic for rapid identification of sepsis that will be evaluated to triage COVID-19 patients for severe outcomes (sepsis) in the ICU and ED. | 599549 | Diagnostic | 6/11/2020 | |
| InBios International, Inc. | SCoV-2 Ab Detect™ Rapid Test | SARS-CoV-2 Ab Detect™ Rapid Test, is a lateral flow serodiagnostic test that will use blood products, including fingerprick blood, to identify persons infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay will detect SCoV-2 reactive antibodies as host biomarkers. | 594943 | Diagnostic | 4/27/2020 | |
| Luminex | ARIES SARS-CoV-2 Assay | Luminex Corporation will develop a sample-to-answer SARS-CoV-2 assay on its IVD ARIES® molecular diagnostic system that can be run in moderate complexity labs. | 642450 | Diagnostic | 3/27/2020 | |
| Luminex | NxTAG CoV Extended Panel | The testing protocol for the NxTAG CoV Extended Panel involves extraction on a bioMerieux system, amplification using Eppendorf mastercycler, and amplicon detection using the Luminex MAGPIX system. | 642450 | Diagnostic | 3/26/2020 | |
| Luminex | xMAP SARS-CoV-2 Advanced Serology Assay | SARS-CoV-2 Advanced Serology Assay for use with the MAGPIX®, Luminex® 200™ IVD xMAP®, and FLEXMAP 3D® Platforms. | 683500 | Diagnostic | 9/23/2020 | |
| Luminex | NxTAG® Respiratory Pathogen Panel v2 | In this project, viral targets on the NxTAG® Respiratory Pathogen Panel (RPP) will be updated, the SARS-CoV-2 target will be added, and the combined panel will be submitted for 510(k) to provide customers a more accurate, longer term syndromic testing solution. | 5389813 | Diagnostic | 9/24/2020 | |
| Luminostics, Inc. | Unspecified | A rapid, smartphone-readout, antigen immunoassay that uses glow-in-the-dark nanomaterials to sensitively and specifically detect SARS-CoV-2 from shallow nasal swabs in 30 minutes or less, first for point-of-care use and later for home use. | 26120000 | Diagnostic | 9/30/2020 | Link |
| MBio Diagnostics, Inc. | MBio COVID-19 Antibody Panel | The MBio COVID-19 Antibody Panel is a high performance point-of-care for seroprevalence studies, to assess exposure and potential immunity to SARS-CoV-2 virus. It may be used an orthogonal method to confirm positive results reported by another method. | 629595 | Diagnostic | 6/17/2020 | |
| Mesa Tech International | Acula COVID-19 Diagnostics Test | Development of the Accula COVID-19 point-of-care test to request Emergency Use Authorization (EUA) from the FDA within two months of the award. | 561330 | Diagnostic | 3/13/2020 | |
| Nanomix | Rapid Antibody Test for COVID-19 | Development of a COVID-19 rapid mobile test to diagnose infection in as little as 15 minutes. The test detects the presence of SARS-CoV-2 antibodies in blood, to indicate current or past COVID-19 infection. This is the same award as the Nanomix antigen test. A single award of $569,647 is funding development of the antigen and antibody tests. | 569647 | Diagnostic | 4/2/2020 | |
| Nanomix | Rapid Antigen Test for COVID-19 | Development of a COVID-19 rapid mobile test to diagnose infection is as little as 15 minutes. The test detects the presence of SARS-CoV-2 antigen in nasal and throat swabs. This is the same award as the Nanomix antibody test. A single award of $569,647 is funding development of the antigen and antibody tests. | N/A | Diagnostic | 4/2/2020 | |
| NOWDiagnostics Inc. | ADEXUSDx® COVID-19 Test | The ADEXUSDx® COVID-19 test is a rapid and accurate point of care lateral flow assay for detection of SARS-CoV-2 antibodies in blood that utilizes the NOWDiagnostics® ADEXUSDx® device platform. This platform is already commercialized for other tests, including an FDA cleared professional use pregnancy test that is CE marked for self-testing. | 695500 | Diagnostic | 8/27/2020 | |
| OraSure Technologies, Inc | OraQuick® Coronavirus Rapid Antigen Test | Rapid Coronavirus point-of-care test (POC) and potentially in-home, minimally invasive, appropriate for oral fluid and capable of providing results in 30 minutes. | 710310 | Diagnostic | 4/2/2020 | |
| OraSure Technologies, Inc | ELISA based Coronavirus Antibody Test | ELISA based Coronavirus Antibody Test and non-invasive collection device for the detection of anti-SARS-CoV-2 antibodies in oral fluid specimens. Sample collection can be obtained at home, promoting social distancing and reducing risk to health workers. | 629217 | Diagnostic | 6/5/2020 | |
| Ortho Clinical Diagnostics | VITROS® Anti-SARS-CoV-2 IgG Test | High-accuracy immunoassay for the qualitative detection of IgG antibodies to SARS-CoV-2 – which appear in later phases of infection and remain elevated after recovery – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho total antibody test. | 13528000 | Diagnostic | 6/12/2020 | Additional funding for the IgG test and Total tests and new funding for the Ag (Antigen) Test was awarded on 9/18/20, totaling $12.85 million. This built on earlier funding of $678,000. |
| Ortho Clinical Diagnostics | VITROS® Anti-SARS-CoV-2 Total Test | High-accuracy immunoassay for the qualitative detection of total (IgG, IgM, IgA, and other) antibodies to SARS-CoV-2 – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho IgG test. | N/A | Diagnostic | 6/12/2020 | |
| Ortho Clinical Diagnostics | VITROS® SARS-CoV-2 Ag (Antigen) Test | High accuracy immunoassay, for the semi-quantitative detection of Total and IgG antibodies to SARS-CoV-2 & for the qualitative detection of SARS-CoV-2 antigens. | N/A | Diagnostic | 9/18/2020 | |
| Quanterix | Unspecified | A laboratory antigen test with ultra-sensitive single-molecule immunoassay technology to enable detection from a variety of sample types including nasopharyngeal, saliva or self-acquired blood from a finger prick. Sample collection, transport, and processing will occur within 24-48 hours using existing sample collection logistics infrastructure through a network of centralized labs. | 18200000 | Diagnostic | 9/29/2020 | Link |
| Qiagen, LLC | QIAstat-Dx Respiratory SARS-CoV-2 Panel | Qiagen will develop a COVID-19 test, QIAstat-Dx RPS2, to be added to the QIAstat-Dx Respiratory Panel. | 598191 | Diagnostic | 3/12/2020 | |
| Quidel Corporation | Point of Care SARS-CoV-2 Sofia 2 Antigen Assay | Implement SARS-CoV-2 viral antigen assay into a 4-analyte antigen test (SARS-CoV-2, RSV, Flu A and Flu B) on the Quidel Sofia 2 POC Multiplex platform. | 634643 | Diagnostic | 5/29/2020 | |
| Siemens Healthineers | Atellica® IMT SARS-CoV-2 Total (COV2T) assay | The SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the Atellica® IMT system. One award of $602,275 is funding continued development of this assay and the ADVIA Centaur® assay. | 13602275 | Diagnostic | 5/29/2020 | $13,000,000 in additional funding for both the Atellica and ADVIA assays was awarded on 9/17/20. This built on earlier funding of $602275. |
| Siemens Healthineers | ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay | The ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the ADVIA Centaur® XP and ADVIA Centaur® XPT systems. | N/A | Diagnostic | 5/29/2020 | |
| Sonica Health | Sonica's Bio-Integrated, Wireless Sensor System (ADAM) System | Individuals infected with SARS-CoV-2 and similar viruses typically only seek diagnostic tests once they begin exhibiting symptoms. Sonica aims to disrupt this health-care paradigm by detecting infection in individuals before the onset of noticeable symptoms. | 656420 | Diagnostic | 6/29/2020 | |
| Tangen Biosciences | Tangen SARS-SoV-2 Assay | Development of a Point of Care SARS-CoV-2 Assay for use with the Tangen GeneSpark Molecular diagnostic system | 696000 | Diagnostic | 4/15/2020 | |
| Ubiquitome | Unspecified | A battery-operated, mobile RT-PCR device that detects viral RNA with high accuracy in 40 minutes and reports results via its proprietary iPhone app. It offers high throughput and could be much lower cost than lab-based RT-PCR tests. The device is targeted for use in rural and metropolitan hospitals and mobile labs. | 700000 | Diagnostic | 9/29/2020 | Link |
| Vela Diagnostics USA, Inc. | ViroKeyTM SARS-CoV-2 RT-PCR | Probe-based reverse transcriptase PCR (RT-PCR) test | 224780 | Diagnostic | 3/27/2020 | |
| Visby Medical | Unspecified | A palm-sized, single-use RT-PCR device that detects viral RNA with highly accurate results at the point of care in 30 minutes. The device was designed to be used by a person with minimal skills. This novel, versatile technology platform can also be adapted to provide simple, rapid tests for other diseases such as chlamydia, gonorrhea, and influenza. | $9623789 | Diagnostic | 9/29/2020 | Link |
| Cerus Corporation | Intercept Blood System | The Cerus INTERCEPT Blood System reduces the risk of transfusion-transmitted infections from bacteria and other blood-borne pathogens | 1048348 | Other | 4/18/2020 | |
| Colorado State University | SolaVAX Vaccine Development | SolaVAX™ is an inactivated virus vaccine platform that uses Riboflavin and UV light to selectively inactivate virus particles by directed damage to nucleic acids while preserving the integrity of the proteins and viral antigens. | 699994 | Other | 6/25/2020 | Link |
| Phillips North America | Phillips Lumify Ultrasounds | BARDA & Philips Research are collaborating to expand the capability of their compact Philips Lumify, an AI-based multi-functional hand-held ultrasound system, with predictive machine-learning (ML) algorithms, to provide Automatic and Intelligent Quantitative Assessment of Lung Injuries, Diseases and Traumatic Injuries in a Mass-Casualty Incident. | 34893033.36 | Other | 5/8/2020 | |
| Snapdragon Chemisty, Inc. | Continuous Manufacturing for Ribonucleotide Triphosphates | Rapidly scalable continuous manufacturing platform for the chemical synthesis and purification of ribonucleotide triphosphates (NPT) from shelf-stable ribonucleotide. | 691878 | Other | 6/11/2020 | Link |
| VitalConnect | Vista Solution | Vista Solution is an FDA cleared remote patient monitoring system for use within hospital, nursing home facilities, and homes. Vista Solution is comprised of the VitalPatch biosensor, a tablet where vital signs are viewed and transmitted to a central cloud, a secure cloud, and a central monitoring hub. | 592791 | Other | 5/20/2020 | |
| Becton Dickinson | Needles and syringes | Needles and syringes | 42303230 | Vaccine Administration | 7/8/2020 | Link Joint with JPEO-CBRND |
| Corning Incorporated | Corning Valor® Glass vials | Vaccine vials | 204000000 | Vaccine Administration | 6/9/2020 | Link Joint with JPEO-CBRND |
| Esperovax, Inc | Egress RD mRNA Oral Cellular Vaccine Delivery Technology | An oral immunization for COVID-19 involving delivery of enveloped virus like particles (eVLPs) by capsule to the gut that will induce immune protection against disease. | 606780 | Vaccine Administration | 7/28/2020 | |
| University of Connecticut | Single-Administration Microneedle Skin Patch for Pandemic Vaccine | An easy-to-use vaccine-delivery microneedle (MN) patch (i.e., Micro Array Patch) that will contain the spike protein (the S-protein on the shell of COVID-19 virus) and be programmed to automatically deliver this S-protein (as an antigen against COVID-19) into the skin. | 432990 | Vaccine Administration | 8/17/2020 | |
| Vaxess Technologies, Inc. | MIMIX-COVID Pre-fusion Spike Protein Micro Array Patch | MIMIX Vaccine Patch Development and Scaling of shelf-stable, self-applied, single-dose Micro Array Patch (MAP) technology | 749000 | Vaccine Administration | 8/9/2020 | |
| Verndari, Inc. | VaxiPatch™ Complete Vaccination Kit | SARS-CoV-2 Recombinant Spike Receptor Binding Domain protein administered via Micro Array Patch (MAP) Technology | 698215 | Vaccine Administration | 7/23/2020 | |
| SiO2 Materials Science | Vaccine vials | Vaccine vials | 143000000 | Vaccine Administration | 6/8/2020 | Link Joint with JPEO-CBRND |
| Smiths Medical, Inc. | Needles and syringes | Needles and syringes | 20663774 | Vaccine Administration | 7/11/2020 | Link |
| Retractable Technologies, Inc. | Needles and syringes | Needles and syringes | 53664286 | Vaccine Administration | 7/1/2020 | Link Joint with JPEO-CBRND |
| 98point6 | Text-based virtual care to assess, diagnose and treat COVID-19 | The 98point6 primary care platform combines a telehealth service with AI and machine learning to provide a comprehensive program of diagnosis, assessment, triage, reporting and tracking of SARS-CoV-2 infections to a national population of patients. | 700000 | Rapidly Deployable Capabilities | 9/10/2020 | |
| Beckman Coulter | Monocyte Distribution Width (MDW) and Algorithms for Sepsis Detection | Beckman Coulter, in collaboration with Dascena, Inc., is developing a novel machine-learning-based sepsis detection algorithm for regulatory clearance that combines laboratory test parameter values with electronic health record information to accurately predict and detect sepsis earlier. | 2263790 | Rapidly Deployable Capabilities | 5/15/2020 | |
| Current Health | Continuous Monitoring Platform & Algorithm for COVID-19 Severity | A FDA-cleared Artificial Intelligence-powered continuous remote patient monitoring platform that utilizes a wearable vital-signs sensor, integrates with other devices and includes symptom chatbot and video visit functionality. The platform continuously collects respiratory rate, oxygen saturation, mobility, pulse rate and body temperature data. | 699583 | Rapidly Deployable Capabilities | 9/25/2020 | |
| Cytovale Inc. | Rapid Sepsis Diagnostic | Cytovale’s rapid sepsis diagnostic leverages advances in microfluidics, ultra-high speed imaging, and machine learning to rapidly quantify immune cell dysregulation from a blood sample in minutes to predict the likelihood of sepsis. | 3833363 | Rapidly Deployable Capabilities | 4/7/2020 | |
| Evidation Helath | COVID-19 Detection & Forecasting Model Pilot | Evidation seeks to develop a model that can detect whether an individual has likely been infected with COVID-19 and understand an individual’s susceptibility to infection. | 720000 | Rapidly Deployable Capabilities | 4/17/2020 | |
| AstraZeneca | AstraZeneca SARS-CoV-2 monoclonal antibody combination | A novel monoclonal antibody combination that recognizes and neutralizes SARS-CoV-2 is being developed by AstraZeneca with DARPA and BARDA as a potential preventative and post-exposure treatment to combat COVID-19. | 509650000 | Therapeutic | 10/9/2020 | |
| Eli Lilly | Bamlanivimab | Bamlanivimab (LY-CoV555) is a monoclonal antibody with potent neutralizing activity against SARS-CoV2 and demonstrated ability to reduce the risk of hospitalization when administered to infected patients. | 375000000 | Therapeutic | 10/27/2020 | |
| Emergent Biosolutions | Human immune Globulin for COVID-19 (COVID-19 HIG) | HIG is derived from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that target the SARS-CoV-2 virus. Using their established manufacturing process that supports VIGIV, Anthrasil and other FDA approved products, Emergent will purify and concentrate the virus-targeting antibodies into a drug product that can be administered intravenously as a potential therapeutic. | 14531801 | Therapeutic | 4/2/2020 | |
| Genentech USA, Inc. | MSTT1041A (anti-ST2) and UTTR1147A (IL-22Fc) | ST2 is the receptor for IL-33. Inhibition of IL-33 signaling via inhibition of ST2 is predicted to reduce maladaptive hyperinflammatory responses. IL22 is a cytokine that promotes epithelial and endothelial cell repair and may prevent secondary bacterial infections. | 22600000 | Therapeutic | 5/28/2020 | |
| Genetech USA, Inc. | ACTEMRA (tocilizumab) | Tocilizumab is a recombinant anti-human monoclonal antibody directed against the interleukin-6 receptor (IL-6R) | 25100000 | Therapeutic | 3/27/2020 | |
| Grifols Shared Services North America, Inc. (Grifols) | Convalescent plasma and hyperimmune globulin | Both products originate from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that specifically target the SARS-CoV-2 virus. To produce convalescent plasma, the donated plasma will be pathogen inactivated and made available in units for infusion as an investigational therapeutic. Grifols will also purify and concentrate the virus-targeting antibodies into an investigational therapeutic called hyperimmune globulin. | 12551764.05 | Therapeutic | 4/7/2020 | |
| Janssen Research & Development, LLC | SARS-CoV-2 Therapeutic Drug Screening Efforts | Janssen, in collaboration with Rega Institute of Medical Research, will screen libraries to identify therapeutic compounds with antiviral activity against 2019-nCoV. | 152312126 | Therapeutic | 2/14/2020 | |
| Regeneron Pharmaceuticals, Inc | REGN-COV2 (SARS-CoV-2 specific monoclonal antibodies) | Develop multiple monoclonal antibodies that, individually or in combination, could be used against the novel coronavirus SARS-CoV-2 that causes COVID-19 | 617724874 | Therapeutic | 7/6/2020 | |
| Regeneron Pharmaceuticals, Inc | Sarilumab | Kevzara (sarilumab) is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. | 69886334 | Therapeutic | No longer supported | |
| SAb Biotherapeutics, Inc. | SAB-185 | SAB-185 is a novel high-potency immunotherapy candidate designed to treat COVID-19. The therapy delivers human polyclonal antibodies targeted specifically to the SARS-CoV-2 virus, that are generated, collected and purified using SAB’s proprietary in vivo platform technology, without the need for human donors or serum from recovered coronavirus patients. | 7200000 | Therapeutic | 3/30/2020 | |
| AstraZeneca | AZD1222 (formerly ChAdOx1 nCoV-19 vaccine) | The AZD1222 vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the structural surface glycoprotein (Spike protein) antigen of the SARS CoV-2 (nCoV-19) | 1200000000 | Vaccine | 5/20/2020 | |
| Janssen Research & Development, LLC | Viral Vector Vaccine for COVID-19 | Support development to licensure of a vaccine to combat COVID-19 using Janssen’s established Adenovirus 26 platform, plus demonstration of Janssen's capacity to perform large scale manufacturing domestically of up to 100 million doses of its SARS-CoV-2 vaccine, Ad26.COV2.S | 1457887080 | Vaccine | 8/5/2020 | |
| Merck and IAVI | rVSVΔG-CoV2 | Recombinant vesicular stomatitis virus (VSVΔG)-vectored vaccine expressing the spike protein of SARS-CoV-2. | 38033570 | Vaccine | 4/15/2020 | |
| ModernaTX, Inc. | SARS-CoV-2 mRNA-1273 vaccine | mRNA based SARS-CoV-2 vaccine encoding a pre-fusion stabilized Spike protein | 2479894979 | Vaccine | 5/24/2020 | |
| Novavax, Inc. | NVX-CoV-2373 Vaccine for SARS-CoV-2 | Manufacture and delivery of SARS-CoV-2 vaccine doses, NVX-CoV2373, which is suitable for use in humans under a sufficiently informed deployment strategy, and the advanced positioning of a stockpile of critical long lead raw materials for the Matrix-M adjuvant. The NVX-CoV-2373 vaccine is comprised of the Matrix-M™ adjuvant, and antigen (SARS-CoV-2 spike protein). | 1600434523 | Vaccine | 7/6/2020 | |
| Pfizer Inc. | BNT162, a prototype COVID-19 mRNA vaccine | Pfizer will conduct large-scale manufacturing and fill-finish of 100M doses of its prototype COVID-19 mRNA vaccine, developed in collaboration with BioNTech, for distribution in the US once Emergency Use Authorization or licensure is granted by the FDA. | 1950000000 | Vaccine | 7/22/2020 | |
| Sanofi and GlaxoSmithKline | Recombinant SARS-CoV-2 Protein Antigen + AS03 Adjuvant | Recombinant SARS-CoV-2 spike protein with transmembrane region deleted produced using Sanofi’s FDA-licensed seasonal influenza vaccine Flublok® facilities, adjuvanted with GSK's AS03 | 2072775340 | Vaccine | 7/31/2020 | |
| Cytiva | N/A | Manufacturing Capacity for COVID-19 Vaccines | 31190000 | Vaccine/Therapeutic Manufacturing | 10/13/2020 | Link |
| Emergent BioSolutions | N/A | Manufacturing capacity for Operation Warp Speed candidates | 658250000 | Vaccine/Therapeutic Manufacturing | 8/6/2020 | Link |
| Grand River Aseptic Manufacturing | N/A | Manufacturing capacity for vaccine and therapeutic candidates | 160000000 | Vaccine/Therapeutic Manufacturing | 8/3/2020 | Link |
| Texas Center for Innovation in Advanced Development and Manufacturing | N/A | Manufacturing Capacity for COVID-19 Vaccines | 264693063 | Vaccine/Therapeutic Manufacturing | 7/24/2020 | Link |
| Thermo Fisher Scientific | N/A | Manufacturing Capacity for COVID-19 Vaccines | 49189402 | Vaccine/Therapeutic Manufacturing | 6/13/2020 | Link |
| Ology Bioservices, Inc. | N/A | Fill/finish manufacturing capacity for COVID-19 vaccines and therapeutics | 106300002 | Vaccine/Therapeutic Manufacturing | 8/17/2020 | Link |
| TOTAL | 14,491,620,835 |